|
|
Volumn 5, Issue 10, 2009, Pages 521-522
|
|
Are new agents needed to treat RA?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABATACEPT;
ADALIMUMAB;
ATLIZUMAB;
CERTOLIZUMAB PEGOL;
CYCLIC CITRULLINATED PEPTIDE ANTIBODY;
DISEASE MODIFYING ANTIRHEUMATIC DRUG;
ETANERCEPT;
GOLIMUMAB;
HLA DR ANTIGEN;
INFLIXIMAB;
RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
RITUXIMAB;
TUMOR NECROSIS FACTOR;
BIOLOGICAL THERAPY;
CD4+ T LYMPHOCYTE;
CIGARETTE SMOKING;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MARKETING;
DRUG TARGETING;
DRUG TREATMENT FAILURE;
EDITORIAL;
GENETIC SUSCEPTIBILITY;
HUMAN;
PRIORITY JOURNAL;
REMISSION;
RHEUMATOID ARTHRITIS;
RISK FACTOR;
T LYMPHOCYTE ACTIVATION;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
DISEASE-FREE SURVIVAL;
DRUG DISCOVERY;
HUMANS;
INDIVIDUALIZED MEDICINE;
PATIENT SATISFACTION;
REMISSION INDUCTION;
RHEUMATOLOGY;
|
|
EID: 70349966205
PISSN: 17594790
EISSN: 17594804
Source Type: Journal
DOI: 10.1038/nrrheum.2009.197 Document Type: Editorial |
|
Times cited : (13)
|
|
References (0)
|